ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Fecal Transplants: a New Treatment for IBD
Linda Ann Sasser has had ulcerative colitis since she was 20, but it wasn’t until May 2019, about 30 years later, that her condition hit a low point: not only did she have a major flare-up of chronic inflammatory bowel disease (IBD), but on top of it, she had Clostridioides difficile (or C. diff), a highly contagious bacterial infection that causes severe diarrhea and inflammation of the colon. “I became really, really sick with bloody diarrhea 30 times a day and chronic stomach pain,” Sasser says. While hospitalized for 12 days, she was given oral steroid medications, which didn’t help, then IV ste...
Source: TIME: Health - September 9, 2021 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized Disease feature Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How does Lichen Sclerosus et Atrophicus Present?
Discussion Lichen sclerosus et atrophicus (LSA) is a chronic inflammatory disease with a strong autoimmune association. It can occur with other autoimmune diseases. Its specific cause is unknown. It affects females and males of all ages, but especially females 40-60 years. In the pediatric population it affects prepubertal females most often. Treatment includes steroid medications or anti-inflammatory medications. Other treatments may be offered including phototherapy, and much less commonly systemic steroids or immunosuppressive therapy. Circumcision may also be an option for some males. Childhood LSA generally improves b...
Source: PediatricEducation.org - September 6, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Approval supported by data from one of the largest registrational Phase 3 programs in atopic dermatitis evaluating RINVOQ (upadacitinib) monotherapy or with topical corticosteroids[1] RINVOQ met all primary and secondary endpoints, demonstrating rapid a... Biopharmaceuticals, Dermatology, Regulatory AbbVie, RINVOQ, upadacitinib, atopic dermatitis, JAK inhibitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 24, 2021 Category: Pharmaceuticals Source Type: news

Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks
The JAK inhibitor shows efficacy and safety when used in combination with topical corticosteroids, and showed superiority in a head-to-head comparison with dupilumab.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 19, 2021 Category: Dermatology Tags: Allergy & Clinical Immunology News Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Continuous Corticosteroids Best for Mild, Well-Controlled, Asthma? Continuous Corticosteroids Best for Mild, Well-Controlled, Asthma?
Discontinuing ICS may make sense for some patients with well-controlled asthma, but some patients with mild and well-controlled disease may fare better by continuing treatment, according to a study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 12, 2021 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 10th August 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily. We are continually monitoring the evidence and updating the guideline as new information emerges. Priority areas for update include recommendations on heparins. On 10 August 2021, we corrected an error in the practical info section of the recommendations on corticosteroids. The dose of prednisolone for c...
Source: Current Awareness Service for Health (CASH) - August 12, 2021 Category: Consumer Health News Source Type: news

Sjogren's Syndrome With Nervous System Injury and Cryptococcosis Sjogren's Syndrome With Nervous System Injury and Cryptococcosis
This case details a rare form of neural involvement in Sjogren's syndrome, combined with pulmonary and osseous cryptococcosis due to long-term use of high-dose corticosteroids and immunosuppressants.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Waiting 3 Months After Corticosteroid Injections for TKA Waiting 3 Months After Corticosteroid Injections for TKA
When is it safe to administer corticosteroid injections in TKA patients? A new study aims to determine the optimal timing.Journal of the American Academy of Orthopaedic Surgeons (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 11, 2021 Category: Surgery Tags: Orthopaedics Journal Article Source Type: news

Are corticosteroids given orally or by injection an effective treatment for people with COVID-19?
 Are corticosteroids (anti-inflammatory medicines) given orally or by injection an effective treatment for people with COVID-19?Key messagesCorticosteroids (anti-inflammatory medicines) given orally or by injection (systemic) are probably effective treatments for people hospitalised with COVID-19.   The authors don’t know whether they cause unwanted effects. The authorsdon ’t know which systemic corticosteroid is the most effective. They found no evidence about people without symptoms or with mild COVID-19 who were not hospitalised. They found 42 ongoing studies and 16 completed studies that...
Source: Cochrane News and Events - August 10, 2021 Category: Information Technology Authors: Katie Abbotts Source Type: news

Short-Acting Beta Agonist Overuse'a Global Public Health Issue'Short-Acting Beta Agonist Overuse'a Global Public Health Issue '
Overreliance on SABAs and underuse of inhaled corticosteroids are associated with increased risk of exacerbations and asthma-related death.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 12, 2021 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

SLE Neuropsych Event Etiology Helps Define Predictors, Outcomes SLE Neuropsych Event Etiology Helps Define Predictors, Outcomes
Male sex, active systemic lupus erythematosus, and corticosteroid use were among the factors positively associated with neuropsychiatric events in patients with SLE.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 10, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being pr...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients
Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids. (Source: University of Bristol news)
Source: University of Bristol news - July 6, 2021 Category: Universities & Medical Training Tags: Alumni, Health, International, Postgraduate, Public engagement, Publications, Research; Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news

Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients
(King's College London) Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 6, 2021 Category: International Medicine & Public Health Source Type: news

Medical costs higher for RA patients receiving corticosteroids and those with DM in Japan
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news

Roche's Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). (Source: World Pharma News)
Source: World Pharma News - June 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche ’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra ® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The E UA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVI...
Source: Roche Media News - June 25, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra ® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The E UA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVI...
Source: Roche Investor Update - June 25, 2021 Category: Pharmaceuticals Source Type: news

US, International MIS-C Studies Yield Disparate Results US, International MIS-C Studies Yield Disparate Results
Both show that current treatments are effective, but one found better outcomes with immunoglobulin plus corticosteroid therapy, the other, no difference with combination therapy vs single-agent treatments.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - June 17, 2021 Category: Emergency Medicine Tags: Pediatrics News Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 news from Annals of Internal Medicine
(American College of Physicians) Experts suggest limited and careful use of corticosteroids as one of several strategies to curtail the syndemic of mucormycosis, or 'black fungus,' a fungal infection characterized by blackening or discoloration over the face, breathing difficulties, and other serious symptoms, that has recently emerged in India. A commentary from Washington University School of Medicine and the University of Massachusetts Medical School is published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 7, 2021 Category: Infectious Diseases Source Type: news

What Are Some Indications for Using Dexamethasone?
Discussion Corticosteroids are a group of drugs which can be naturally or synthetically produced. Naturally occurring substances are produced in the adrenal gland, and are protein-bound (primarily corticosteroid-binding globulin and albumin). In the target tissues, they may need to be converted to an active substance. They are then reduced, oxidized, hydroxylated or conjugated as measures to inactivate them. Synthetic steroids have less protein binding and depending on their structure are more or less resistant to inactivation. Prednisone is the glucocorticoid most often used for treatment, especially as it has a short hal...
Source: PediatricEducation.org - June 7, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Mitigating the impacts of COVID-19: where are the mental health trials?, Lancet Psychiatry
COVID-19 prompted rapid mobilisation of health services and medical science in the face of unprecedented challenges. When COVID-19 emerged in 2020, medical science delivered, and delivered quickly. Using large-scale multicentre trials, researchers in partnership with health services established the ability of cheap and scalable interventions (such as corticosteroids) to save lives, and rapidly showed the futility of anecdotally endorsed repurposed drugs (such as hydroxychloroquine). The effectiveness of vaccinations was quickly established in phase 2 and 3 trials, providing the confidence to roll out successful vaccine pro...
Source: Current Awareness Service for Health (CASH) - June 4, 2021 Category: Consumer Health News Source Type: news

Drug-Induced Immunosuppression Examined in U.S. Adults
WEDNESDAY, June 2, 2021 -- Overall, 2.8 percent of a national cohort of commercially insured U.S. adults meet criteria for drug-induced immunosuppression, of whom 67.7 percent receive oral corticosteroids, according to a research letter published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 2, 2021 Category: Pharmaceuticals Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Add-On Voclosporin Improves Outcome in Lupus Nephritis Add-On Voclosporin Improves Outcome in Lupus Nephritis
Voclosporin plus MMF and low-dose corticosteroids improves renal response rates compared with use of these agents alone in patients with in lupus nephritis, according to a company-funded study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news

Insufficient data on use of inhaled corticosteroids to treat COVID-19, EMA
EMA's COVID-19 taskforce (COVID-ETF) is advising healthcare professionals that there is currently insufficient evidence that inhaled corticosteroids are beneficial for people with COVID-19. Although the taskforce found no safety risks from studies so far, it could not exclude the possibility of harm from the use of inhaled corticosteroids in patients with COVID-19 who have normal levels of oxygen. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 28, 2021 Category: Consumer Health News Source Type: news

Corticosteroid therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials, Medicine
Review of 8 RCTs (n=7,737) found the odds of mortality and need of mechanical ventilation were significantly lower in patients who received corticosteroids vs standard of care (OR 0.85 [95% CI: 0.76; 0.95] P=0.003) and (OR = 0.76 [95% CI: 0.59; 0.97] P=0.030), respectively. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 26, 2021 Category: Consumer Health News Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of lif...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve p...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Corticosteroid Bursts May Increase GI Bleeding Risk in Children Corticosteroid Bursts May Increase GI Bleeding Risk in Children
Oral corticosteroid bursts are associated with an increased risk of gastrointestinal bleeding, sepsis, and pneumonia during the month after treatment initiation, according to a cohort study in Taiwan.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - May 5, 2021 Category: Emergency Medicine Tags: Pediatrics News Source Type: news

Topical Corticosteroid Use in Pregnancy Not Tied to SGA, LBW
WEDNESDAY, May 5, 2021 -- Topical corticosteroid use in pregnancy is not associated with increased risks for small for gestational age (SGA) or low birth weight, according to a study published online May 5 in JAMA Dermatology. Niklas Worm... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 5, 2021 Category: Pharmaceuticals Source Type: news

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet
In patients with hypoxia and evidence of systemic inflammation (C-reactive protein ≥75 mg/L), the addition of tocilizumab to usual standard of care (82% receiving systemic corticosteroids) reduced 28-day mortality (31% v 35%; rate ratio 0.85; 95% CI 0.76–0.94; p=0.0028). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 4, 2021 Category: Consumer Health News Source Type: news

Featured Review: Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
New Cochrane Review on the efficacy and safety of inhalers for those with mild asthma published on World Asthma Day.World Asthma Day on 5 May is an annual event on organized by the  Global Initiative for Asthma (GINA) to improve asthma awareness and care around the world.Cochrane Airways works with authors (typically clinicians and researchers) to produce systematic reviews on chronic obstructive pulmonary disease (COPD), bronchiectasis and other lung diseases, and asthma. We asked Dr Timothy Hinks, one of the Cochrane Review authors, about the findings of this recent review.For those with mild asthma, ...
Source: Cochrane News and Events - April 29, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context, The Lancet Respiratory Medicine
Article reviews clinical& methodological heterogeneity of studies of IL-6 antagonists,& considers how this might have influenced reported treatment effects. Severity of illness and concomitant corticosteroids are among factors that might have contributed to inconsistent results (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 29, 2021 Category: Consumer Health News Source Type: news

Horizontal transmission can cause severe and persistent eye inflammation
This study highlights a novel mode of transmission for HTLV-1 uveitis. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 27, 2021 Category: Infectious Diseases Source Type: news

Separate Corticosteroid Injections From COVID Vaccine by 2 Weeks Separate Corticosteroid Injections From COVID Vaccine by 2 Weeks
Clinicians may still want to time elective corticosteroid injections at least two weeks before or after receipt of this vaccine, according to a group of doctors writing on behalf of the Spine Intervention Society.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - April 26, 2021 Category: Orthopaedics Tags: Infectious Diseases News Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 8th April 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together existing recommendations on managing COVID-19 so that healthcare staff and those planning and delivering services can find and use them more easily. The guideline includes new recommendations on therapeutics, and we will update the guideline further as new evidence emerges. 8 April 2021, Recommendations for using corticosteroids, tocilizumab and sarilumab to treat COVID-19 were added (including the evidence and rationale for making the recommendations). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 15, 2021 Category: Consumer Health News Source Type: news

Topical Dermatologic Corticosteroids: in Vivo Bioequivalence
Biopharmaceutics (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 13, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Common asthma drug speeds up COVID-19 recovery in high-risk patients
A common corticosteroid shortens COVID-19 recovery times for patients aged over 50 who are at high risk of developing severe illness, a groundbreaking GP-led trial has found. (Source: GP Online News)
Source: GP Online News - April 12, 2021 Category: Primary Care Tags: Coronavirus Source Type: news

Common asthma drug speeds up COVID-19 recovery in community for high-risk patients
A common corticosteroid shortens COVID-19 recovery times for patients aged over 50 who are at high risk of developing severe illness, a groundbreaking GP-led trial has found. (Source: GP Online News)
Source: GP Online News - April 12, 2021 Category: Primary Care Tags: Coronavirus Source Type: news

Sobrin Receives Research to Prevent Blindness Physician-Scientist Award
Lucia Sobrin, MD, MPH, of the Division of Ophthalmology, won the Physician-Scientist Award from Research to Prevent Blindness (RPB) for her work in identifying genes that influence the risk of developing ocular hypertension after corticosteroid use. (Source: BWH News)
Source: BWH News - March 29, 2021 Category: Hospital Management Source Type: news

Remdesivir and clinical improvement in hospitalized patients with COVID-19
(JAMA Network) This comparative effectiveness research study that included a high proportion of non-White individuals assesses whether remdesivir administered alone or with corticosteroids is associated with time to clinical improvement or time to death in patients hospitalized with confirmed COVID-19. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 24, 2021 Category: International Medicine & Public Health Source Type: news